medigraphic.com
Asociación Mexicana de Gastroenterología

2007, Number 4

Next >>

Rev Gastroenterol Mex 2007; 72 (4)

Prevalence of hepatitis C virus genotypes in Mexican patients

Dehesa-Violante M, Bosques-Padilla F, Kershenobich-Stalnikowitz D

Language: English
References: 23
Page: 344-348
PDF size: 43.88 Kb.


ABSTRACT

Background: Worldwide HCV studies have documented its large genetic variability; HCV has major genetic groups called genotypes that are designated from 1 to 6, as well as › 50 subtypes. This is very important considering that treatment response varies according to genotype. The purpose of this trial was to ascertain prevalence of HCV genotypes in a group of patients from 10 states in Mexico. Methods: This study enrolled patients from 22 hospitals throughout the country. Patients tested positive to hepatitis C antibody and genotyping was preformed by Lipa method. To carry out a comparison, two regions were arbitrarily defined, the northern region embodied the cities of Culiacan, Torreón, Monterrey, Ciudad Obregón, and Tijuana, while the central-southern region embodied Mexico City, Guadalajara, León, Puebla, and Veracruz. Results: The test was performed on a total of 421 patients. The most frequently found genotype was genotype 1, present in 70.55% of cases. The majority (40.1%) corresponded to genotype 1b, 17.81% to 1a, and genotype 2a/2c (11.64%). A total of 29.4% of samples corresponded to genotypes non-1. Genotype 1 was found in 72.34 (northern region) and 70.03% (central-southern) of the two regions, and genotypes non-1 in 27.66 and 29.97%, respectively. Conclusions: We conclude that the most frequent genotype in Mexico is 1b, followed by 1a, and, in third place 1b1a, for a total of 70.55%; the remaining 29.45% had genotypes other than 1.


REFERENCES

  1. Alter HJ, Seef LB. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Sem Liv Dis 2000; 20: 17-35.

  2. Branch AD. Hepatitis C virus RNA codes for proteins and replicates. Does it also trigger the interferon response? Sem Liv Dis 2000: 20; 57-68.

  3. Tao Q, Wei L, Chang J, Wang H, Sun Y. Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. J Gastroenterol 1998; 33: 684-93.

  4. Farzi P, Pourcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Sem Liv Dis 2000; 20: 103-26.

  5. Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology 1994: 43; 68-76.

  6. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F Irvine B, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 region. J Gen Virol 1993; 74: 2391-9.

  7. Simmonds P, Smith DB, McOmish F, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS5 regions. J Gen Virol 1994; 75: 1053-61.

  8. Simmmonds P, Alberti A, Alter H, Bradley DW, Brechot DW, Brower JT, Chan SW, Cheyama K, Chen DS. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994: 19; 1321 -4.

  9. Fried M, Shiffman ML, Reddy K, Smith C, Marinos J, Gonzales FL, Houssinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Pegylated (40 kDa) Interferon alpha-2a (PEGASYS®) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. N Engl J Med 2002; 347: 975-82.

  10. Hadziyannis SJ, Cheinquer H, Morgan T. Peginterferon alpha-2a (49KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36S1: A-1.

  11. Malé R, Ayuzo del Valle C, Santoscoy Tovar F. Genotipos de hepatitis C en el occidente del país. Rev Gastroenterol Mex 2002; 67(S3): 176-7.

  12. Pérez-Gómez R, Dehesa-Violante M, Olivera-Martínez MA, Bazán-Pérez CV y cols. Evaluación prospectiva de la respuesta temprana con peginterferón Alfa-2ª (40KD) (Pegasys®) y ribavirina de un estudio clínico aleatorizado que examina los efectos de la duración del tratamiento en pacientes con hepatitis C infectados con genotipo 1. Reporte preliminar. Rev Gastroenterol Mex 2002; 67(S3): 141.

  13. Bosques-Padilla F, Muñoz L, Chávez-Oest JA, Cabrera-Valdespino A, Vivar R. Efecto de la duración del tratamiento con peginterferón Alfa-2ª (40KD) (Pegasys®) y de la dosis de ribavirina en pacientes con hepatitis C: análisis de los pacientes mexicanos incluidos en un estudio multinacional. Rev Gastroenterol Mex 2002; 67(S3): 139.

  14. Bosques-Padilla F, Campollo O, Trejo R, Cabrera-Valdespino A, Vivar R. Eficacia y seguridad de Peginterferón Alfa-2ª (40KD) (Pegasys®) en combinación con ribavirina en pacientes con hepatitis C: análisis de los pacientes mexicanos incluidos en un estudio Multinacional. Rev Gastroenterol Mex 2002; 67(S3): 139.

  15. Rizo-Robles, T, López-Fuerte F, Torres-Ibarra R, Dehesa Violante M, Pérez-Gómez R, Poo-Ramírez JL y cols. Estudio de seguridad de peginterferón alfa-2ª (40KD) (Pegasys®) y ribavirina en pacientes con hepatitis C crónica. Reporte preliminar de los pacientes mexicanos incluidos en un estudio multinacional. Rev Gastroenterol Mex 2002; 67(S3): 138.

  16. Trejo R, Bosques F, Campollo O, Cabrera A, Vivar R. Calidad de vida con la terapia de Peginterferón alfa-2ª (40KD) (Pegasys®) en combinación con ribavirina en pacientes con hepatitis C: análisis de los pacientes mexicanos incluidos en un estudio multinacional. Rev Gastroenterol Mex 2002; 67(S3): 138.

  17. Brandao CE, Perez-Gomez R, Pessoa MG, Olivera-Martinez MA, Caramori A, Bazan-Perez CV, Patelli M, Torres-Ibarra R, Barone A, Dehesa-Violante M, Vivar R, Tastch F. Evaluación prospectiva de la respuesta virológica temprana asociada a Peginterferón alfa-2ª (40KD) (Pegasys®) y ribavirina de un estudio fase IV, aleatorizado que examina los efectos de la duración del tratamiento en pacientes con hepatitis C infectados por genotipo 1. Hepatology 2002;36:4-A805.

  18. Van Brussel M, Dekeyser F, Vandoorn LJ, Ziermann, Sablon E. Identification of new type-specific patterns with the Versant HCV genotype Kit (Lipa). J Hepatol 2002; 36(S1): A857.

  19. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 122S -7S.

  20. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova B, Benhamou JP, Erlinger S. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.

  21. Mahaney K. Tedeschi V. Maertens G. et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 1405-11.

  22. Khaja MN, Madhavi C, Thippavazzula R, Nafeesa F, Habib AM, Habibullah CM, Guntaka RV. High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. Infec Genet Evol 2006; 6(3): 198-204.

  23. Suou T, Kawatani T, Nishikawa K, Ueki J, Sawada H, Ooi S, Yamada M, Sasaki H, Kawasaki H. High prevalence of hepatitis C virus genotype la in Japanese hemophiliacs. Inter Hepatol Comm1996; 4(6): 301-4.




2020     |     www.medigraphic.com